Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Background: Imatinib mesylate (IM) is the standard treatment for BCR-ABL-positive chronic myelogenous leukemia (CML) and is the first-line adjuvant and palliative treatment for metastatic and inoperable gastrointestinal stromal tumor (GIST). IM is not known to be associated with an increased risk fo...

Full description

Bibliographic Details
Main Authors: Abbas Agaimy, Valeska Brueckl, Daniela Schmidt, Stephanie Krieg, Evelyn Ullrich, Norbert Meidenbauer
Format: Article
Language:English
Published: Karger Publishers 2013-03-01
Series:Case Reports in Oncology
Subjects:
Gastrointestinal stromal tumor
Imatinib mesylate
Glivec
Tuberculosis
Granuloma
PET-CT
Online Access:http://www.karger.com/Article/FullText/348712

Internet

http://www.karger.com/Article/FullText/348712

Similar Items